NCT02122237

CompletedPhase 3

Cathodal tDCS in Chronic Migraine: Neurophysiological Study ...

University of Liege Source

Compare

Other study identifiers

Sponsor study identifier

CB-1289

Study Type

interventional

Actual enrollment (reported)

14

Locations

1 country

Sites

1

Timeline

Study Start

September 2013

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

April 2014

Actual (reported)

Study Completion

September 2014

Actual (reported)

Brief Summary

Cathodal tDCS decreases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in chronic migraine.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 14 participants
Study completion date: September 2014
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
September 2013
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
November 4, 2013
Actual (reported)
Primary Completion
April 2014
Actual (reported)
First Posted
April 24, 2014
Actual (reported)
Study Completion
September 2014
Actual (reported)

Last Updated: May 28, 2015
Status Verified: May 2015
Last Update Submitted: May 27, 2015

Conditions

Chronic Migraine

Outcome Measures

Primary Outcomes (1)

Migraine frequency
The investigators evaluate migraine frequency at baseline, during the treatment and 2 months after its end.
6 months

Secondary Outcomes (4)

Migraine intensity
6 months
Acute medication intake
6 months
Attack duration
6 months
Scores at psychological scales
6 months

Study Arms (1)

Cathodal Cefaly tDCS

EXPERIMENTAL

Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.

Device: Cefaly tDCS

Interventions

Cefaly tDCSDevice

Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.

Cathodal Cefaly tDCS

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse

You may not qualify if:

Sponsors & Collaborators

University of Liege
Otherlead

Study Sites (1)

Roberta Baschi

Liège, Belgium, 4000, Belgium

Study Officials

Delphine Magis, MD,PhD
University of Liege
PRINCIPAL INVESTIGATOR
Jean Schoenen, MD,PhD
University of Liege
STUDY DIRECTOR

Enrollment

14 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Honorary Full Professor

Study Record Dates

First Submitted

November 4, 2013

First Posted

April 24, 2014

Study Start

September 2013

Date type not reported

This date has not been verified as actual or estimated.

NCT06810505

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Phase 3Recruiting

NCT03855137

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Phase 3Completed

NCT00772031

NINDS CRC Chronic Migraine Treatment Trial

Phase 3Completed

NCT04616326

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Phase 3Active Not Recruiting

NCT07018713

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Phase 3Active Not Recruiting

NCT06047444

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Phase 3Active Not Recruiting

others diseases or contraindications to tDCS (epilepsy, pacemaker, metal prosthetics)

Contact the study team to confirm eligibility.

Primary Completion

April 2014

Actual (reported)

Study Completion

September 2014

Actual (reported)

Last Updated

May 28, 2015

Record last verified: 2015-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02122237
Data provider: ClinicalTrials.gov
Source updated: 2015-05-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:33:43 UTC

Locations

BE(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

Primary Completion

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Study Arms (1)

Cathodal Cefaly tDCS

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations